🇺🇸 FDA
Patent

US 11129844

Compositions and methods for modulating MECP2 expression

granted A61KA61K31/712A61P

Quick answer

US patent 11129844 (Compositions and methods for modulating MECP2 expression) held by Ionis Pharmaceuticals, Inc. expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue Sep 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
29
CPC classes
A61K, A61K31/712, A61P, A61P25/22